Today EBE and EuropaBio’s Joint Rare Diseases and Orphan Medicinal Products Task Force released an assessment of the EU’s Orphan Medicinal Products (OMP) Regulation evaluating the extent to which this legislation has impacted research into rare diseases and the availability of new medicines to treat rare diseases over the last ten years.
Yesterday 22 CEOs from Member State Biotech companies, together with representatives of 11 National
Biotech Associations, converged on Europe’s capital for EuropaBio Brussels Day and a series of
meetings with EU decision makers.
Today, Europabio joins in congratulating the three Nobel Prize winning scientists who have discovered
that the key to successful DNA replication is in the caps at the ends of chromosomes - the telomeres -
and in the enzyme that forms them - telomerase.
EuropaBio, the European Association for Bioindustries, and Venture Valuation, with the collaboration of
national stakeholders, yesterday published a ground-breaking report “Biotech in the new EU Member
States: an emerging sector”...
On June 9, Health Ministers from the 27 EU Member States unanimously signed up to a series of political commitments on behalf of Europe’s rare disease patients, by adopting a Council Recommendation on a European Action in the Field of Rare Diseases.